Table 2.
Characteristics of the 60 patients treated with pemafibrate evaluated by Fibroscan
| Male/female | 36/24 | |
| Age (years) | 57.1 (24–82) | |
| Body height (m) | 163.2 (143–171.8) | |
| Pre-treatment body weight (kg) | 73.5 (53–93.7) | |
| Pre-treatment BMI (kg/m2) | 27.8 (18.3–38.2) | |
| Comorbidities | ||
| T2DM | 23 | 38.3% |
| Chronic hepatitis B | 0 | 0% |
| CAD | 4 | 6.7% |
| IBD | 0 | 0% |
| Other | 10 | 16.7% |
| Biopsy-proven NASH | 2 | 3.3% |
| Pre-treatment laboratory values | ||
| TG (mg/dL) | 272.1±30.7 | |
| HDL-cholesterol (mg/dL) | 48.9±1.6 | |
| LDL-cholesterol (mg/dL) | 120.5±4.7 | |
| AST (U/L) | 52.7±3.9 | |
| ALT (U/L) | 74.3±6.1 | |
| GGT (U/L) | 98.7±11.4 | |
| HbA1c (%) | 6.5±0.2 | |
| FIB-4 index | 2.0±0.2 | |
| APRI | 0.7±0.07 | |
| eGFR (mL/min/1.73m2) | 66.1±14.5 | |
| Type IV collagen (ng/mL) | 4.64±0.9 | |
| Autotaxin (mg/L) | 78.3±11.5 | |
| LSM (kPa) | 9.33±71 | |
| CAP (dB/m) | 318.5±43.3 | |
| FAST Score | 0.45±0.22 | |
| Concomitant medications | ||
| DPP4 antagonist | 11 | 18.3% |
| Metformin | 7 | 11.7% |
| SGLT2 inhibitor | 9 | 15% |
| EPA | 5 | 8.3% |
| Statin | 11 | 18.3% |
| Ezetimibe | 17 | 28.3% |
| UDCA | 11 | 18.3% |
| Duration of pemafibrate administration (weeks) | 113 (101–128) | |
APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; HbA1c, hemoglobin A1c; CAD, coronary artery disease; CT, computed tomography; DPP4, dipeptidyl peptidase-4; EPA, eicosapentaenoic acid; GERD, gastroesophageal reflux disease; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; IBD, inflammatory bowel disease; LDL, low-density lipoprotein; MRI, magnetic resonance imaging; SGLT2, sodium-glucose cotransporter 2; T2DM, type 2 diabetes mellitus; TG, triglyceride; UDCA, ursodeoxycholic acid; US, ultrasonography